Publications by authors named "Udo Mueller"

Claim this Profile
A
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Anthony B El-Khoueiry, Richard D Kim, William P Harris, Max W Sung, Dirk Waldschmidt, Udo Mueller

Hepatology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
Michela Casanova, Francisco Bautista, Quentin Campbell-Hewson, Guy Makin, Lynley V Marshall, Udo Mueller

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z Chang, Tim Larson, Allen L Cohn, Udo Mueller

EClinicalMedicine· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Birgit Geoerger, Bruce Morland, Irene Jiménez, Didier Frappaz, Andrew D J Pearson, Udo Mueller

Eur J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors.
Camille N Abboud, Nicole Lang, Henry Fung, Andreas Lammerich, Anton Buchner, Udo Mueller

Support Care Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
Thomas Wolff, Holger Schulz, Christoph Losem, Dietmar Reichert, Hans-Jürgen Hurtz, Udo Mueller

Eur J Haematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
T Christopher Bond, Erika Szabo, Susan Gabriel, Jean Klastersky, Omar Tomey, Udo Mueller

J Oncol Pharm Pract· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a rat model of moderate liver dysfunction based on alpha-naphthylisothiocyanate-induced cholestasis.
Melanie K Bothe, Christoph Meyer, Udo Mueller, Jean-Christophe Queudot, Virginie Roger

J Toxicol Sci· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Ruth Pettengell, Peter Bias, Udo Mueller, Nicole Lang

Support Care Cancer· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.
Morgan Kruse, Rebecca Wildner, Gisoo Barnes, Monique Martin, Udo Mueller

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
Martin Tallman, Francesco Lo-Coco, Gisoo Barnes, Morgan Kruse, Rebecca Wildner, Udo Mueller

Clin Lymphoma Myeloma Leuk· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Joseph R Mace, Mary L Keohan, Heinz Bernardy, Klaus Junge, Georg Niebch, Udo Mueller

Clin Cancer Res· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic aspects of amino acids production.
Udo Mueller, Susanna Huebner

Adv Biochem Eng Biotechnol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis